The Challenge
There remains considerable variation in the management of lung cancer around the world. Access for patients to important diagnostics, treatments and support programs varies markedly.
Our Solution
ILC2: Initiatives in Lung Cancer Care, a Global Funding Opportunity to Transform Patient Care and Improve the Patient Experience
The ILC2 program supports patient and caregiver organizations registered as non-profit in their country to propose and conduct projects that can potentially transform patient care in countries around the world.
The program recognizes the high variation in lung cancer management around the world, and the very specific local barriers to quality care that must be considered when developing patient-centric solutions to address them.
Over the last 5 years, projects from 28 countries have been granted support to address various points along the patient journey. Please click here to read more about the awarded projects from the previous round 5: https://www.lungambitionalliance.com/News/initiatives-in-lung-cancer-care-round-5-awardees.html
Explore currently funded projects
The program recognizes the high variation in lung cancer management around the world and the very specific local barriers to quality care that must be considered when developing patient centric solutions to address them. Selected projects, awarded in 2020, 2021, 2022, 2023, and 2024 received a total of more than $3.2M. ILC2 projects span the globe, across 28 countries, and target aspects of local areas and country-specific health systems. They outline a variety of approaches – including digital and mobile platform innovation, emotional support groups and hotlines, care for targeted subpopulations, and efforts to improve screening and diagnosis – to address different points along the patient journey.
The Lung Ambition Alliance invites local patient organizations around the world to develop and submit pilot projects that can potentially transform patient care and improve survival at the local level.
Loading......
ILC2 grant applications are reviewed and selected by the Global Lung Cancer Coalition, Guardant Health, and AstraZeneca. Funding for the ILC2 grant is provided by AstraZeneca.
Disclaimer: Grants funding is open to any charitable and registered non-profit organizations involved in the care of patients with lung cancer. The Grants process is supported by the Charities Aid Foundation (CAF). When applying, applicants will be directed to CAF’s carefully selected service provider (Blackbaud) to enter your details. Data provided will only be used for the purposes of assessing your organization's suitability for this program and to inform you of related services provided by Charities Aid Foundation (CAF) and its partners, where such consent has been provided. Please refer to the Privacy Policies of CAF and Blackbaud or more information on how any data provided will be used.
Date of Preparation: October 2023 | Document ID: Z4-59007